Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Debt (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Non-Current Debt for 7 consecutive years, with $20.4 million as the latest value for Q2 2025.

  • Quarterly Non-Current Debt changed N/A to $20.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $20.4 million through Jun 2025, changed N/A year-over-year, with the annual reading at $50285.0 for FY2019, 48.94% down from the prior year.
  • Non-Current Debt for Q2 2025 was $20.4 million at Outlook Therapeutics, down from $21.0 million in the prior quarter.
  • The five-year high for Non-Current Debt was $21.0 million in Q1 2025, with the low at $20.4 million in Q2 2025.